↓ Skip to main content

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Published in
Journal for Immunotherapy of Cancer, July 2018
DOI 10.1186/s40425-018-0387-x
Pubmed ID
Authors

Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson

Abstract

Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve long term outcomes. Eligible patients were HD IL-2 eligible with metastatic BRAF V600 mutated melanoma. Cohort 1 was treatment naïve and received vemurafenib 960 mg BID for 6 weeks before HD IL-2. Cohort 2 received vemurafenib for 7-18 weeks before enrollment. Both cohorts received HD IL-2 at 600,000 IU/kg every 8 h days 1-5 and days 15-19. The primary objective was to assess complete responses (CR) at 10 weeks ±3 (assessment 1) and 26 weeks ±3 (assessment 2) from the start of HD IL-2. Fifty-three patients were enrolled, (cohort 1, n = 38; cohort 2, n = 15). Of these, 39 underwent assessment 1 and 15 assessment 2. The CR rate at assessment 1 was 10% (95% CI 3-24) for both cohorts combined, and 27% (95% CI 8-55) at assessment 2. Three-year survival was 30 and 27% for cohort 1 and cohort 2, respectively. No unexpected toxicities occurred. A shift in the melanoma treatment landscape during this trial adversely affected accrual, leading to early trial closure. Vemurafenib in sequence with HD IL-2 did not change the known toxicity profile for either agent. Lower than expected response rates to vemurafenib were observed. Overall response rates and durability of responses appear similar to that observed with HD IL-2 alone. NCTN, NCT01683188. Registered 11 September 2012, http://www.clinicaltrials.gov/NCT01683188.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 17%
Researcher 4 17%
Student > Bachelor 3 13%
Student > Doctoral Student 2 8%
Professor 1 4%
Other 3 13%
Unknown 7 29%
Readers by discipline Count As %
Medicine and Dentistry 7 29%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Psychology 2 8%
Computer Science 1 4%
Nursing and Health Professions 1 4%
Other 1 4%
Unknown 10 42%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2018.
All research outputs
#7,169,556
of 13,370,991 outputs
Outputs from Journal for Immunotherapy of Cancer
#583
of 784 outputs
Outputs of similar age
#121,094
of 268,323 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 13,370,991 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 784 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,323 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them